Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Articles
25.10.2022
How is International Reference Pricing used within...

We discuss the advantages and disadvantages of using international reference pricing for consistent ...

Read more
Publications
19.10.2022
ISPOR 2022: Changing landscape of Orphan Drug Reim...

We compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...

Read more
Insider Insights
18.10.2022
US Pharma Amylyx in hot water over exorbitant pric...

Amylyx has set the annual price of the ALS drug to $158,000, whereas ICER have suggested the drug sh...

Read more
Articles
18.10.2022
What are the pricing considerations when launching...

We explore the pricing dynamics of biosimilars, which depend on the type of biosimilar, its indicati...

Read more
Publications
12.10.2022
ISPOR 2022: Is International Reference Pricing app...

In our research, we determine how consistently IRP is applied in pharmaceutical price re-evaluation ...

Read more
Insider Insights
12.10.2022
France: Implications for Pharma of the proposed So...

Leem report the changes set out by the Government will heighten the difficulties already being faced...

Read more
Articles
21.09.2022
Pricing and reimbursement of cell and gene therapi...

Introduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...

Read more
Articles
21.09.2022
Are payers willing to pay for innovation for gene ...

Introduction Gene and CAR-T cell therapies are often heralded as the future of healthcare, where gro...

Read more
Articles
24.08.2022
Is NRDL inclusion in China really the golden ticke...

Introduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.